Recommendations on use of systemic treatments for immune-mediated dermatologic disorders in patients with confirmed COVID-19 infection: A rapid review
Dermatologica Sinica
; 40(2):67-70, 2022.
Article
in English
| EMBASE | ID: covidwho-1957509
ABSTRACT
With the rapid outbreak of the coronavirus disease 2019 (COVID-19) pandemic, considerable concerns about the safety of systemic treatments of immune-mediated dermatologic disorders has been raised by dermatologists and their patients. We aimed to perform a rapid review of latest American and European guidelines on the use of systemic treatments in patients with immune-mediated dermatologic disorders and confirmed COVID-19 infection and to provide recommendations to inform practice. Based on the current limited guidelines and evidence, systemic corticosteroids should not be abruptly discontinued and the lowest effective dose should be continued. Systemic immunosuppressants (including methotrexate, cyclosporine, azathioprine, cyclophosphamide, and leflunomide), biologics, and sulfasalazine should be withheld in patients with confirmed COVID-19 infection. Whether to continue Janus kinase inhibitors should be determined following a shared decision-making process between dermatologists and patients after considering patients' medical conditions and risk for severe COVID.
adult; atopic dermatitis; bullous dermatitis; coronavirus disease 2019; dermatologist; human; low drug dose; practice guideline; psoriasis; review; shared decision making; skin disease; systemic therapy; azathioprine; biological product; corticosteroid; cyclophosphamide; cyclosporine; immunosuppressive agent; Janus kinase inhibitor; leflunomide; methotrexate; salazosulfapyridine
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Type of study:
Reviews
Language:
English
Journal:
Dermatologica Sinica
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS